MIDD0301 – A first-in-class anti-inflammatory asthma drug targets GABA(A) receptors without causing systemic immune suppression

We report a 28-day repeat dose immunotoxicity evaluation of investigational drug MIDD0301, a novel oral asthma drug candidate that targets gamma amino butyric acid type A receptors (GABA(A)R) in the lung. The study design employed oral administration of mice twice daily throughout the study period w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Basic Clin Pharmacol Toxicol
Main Authors: Zahn, Nicolas M., Huber, Alec T., Mikulsky, Brandon Nicholas, Stepanski, Mae Elizabeth, Kehoe, Alexander Scott, Li, Guanguan, Schussman, Melissa, Rashid Roni, M. S., Kodali, Revathi, Cook, James M., Stafford, Douglas C., Steeber, Douglas A., Arnold, Leggy A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6565495/
https://ncbi.nlm.nih.gov/pubmed/30694594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcpt.13206
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados